Anti-PIAS2 antibody
Specifications
| Product Cat#: | AB-07-3478 |
| Product type: | Primary antibody |
| Antigen: | PIAS2 |
| Immunogen: | A synthetic peptide derived from human PIAS2. The exact amino-acid sequence is proprietary. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:500-1:2500); ELISA (1:20000) |
| Reactivity: | Human, Mouse, Rat |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | PBS (without Mg2+ and Ca2+ ), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol |
| Concentration: | 1 mg/ml |
| Purity: | Antigen affinity chromatography |
| Storage: | Aliquot and freeze at -20°C. Avoid multiple freeze/thaw cycles. |
| Alternative names: | ARIP3; Androgen receptor-interacting protein 3; DAB2-interacting protein; Msx-interacting zinc finger protein; PIAS-NY protein; PIASX; Protein inhibitor of activated STAT x; Protein inhibitor of activated STAT2 |
Target information
Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulator in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. The effects of this transcriptional coregulation, transactivation or silencing may vary depending upon the biological context and the PIAS2 isoform studied. However, it seems to be mostly involved in gene silencing. Binds to sumoylated ELK1 and enhances its transcriptional activity by preventing recruitment of HDAC2 by ELK1, thus reversing SUMO-mediated repression of ELK1 transactivation activity. Isoform PIAS2-beta, but not isoform PIAS2-alpha, promotes MDM2 sumoylation. Isoform PIAS2-alpha promotes PARK7 sumoylation. Isoform PIAS2-beta promotes NCOA2 sumoylation more efficiently than isoform PIAS2-alpha. Isoform PIAS2-alpha sumoylates PML at’Lys-65′ and ‘Lys-160’.
Provider
Erpantech Laboratory
